Skip to main content

Table 1 Baseline characteristics between treatment groups

From: Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

Characteristic Mepolizumab
(n = 36)
Benralizumab
(n = 19)
p-value
Mean age (range) 53.8 (33–79) 59.6 (23–77) 0.0839
Sex    0.7028
 Female, n (%) 17 (47) 10 (53)  
 Male, n (%) 19 (53) 9 (47)  
Smoking history    0.8406
 Never, n (%) 23 (64) 11 (58)  
 Former, n (%) 7 (19) 5 (26)  
 Active, n (%) 3 (8) 3 (16)  
 No history available, n (%) 3 (8) 0 (0)  
 Mean # of comorbidities 2.3 (0–9) 3.2 (0–9) 0.1363
Comorbid lung disease    0.7652
 Yes, n (%) 10 (28) 6 (32)  
 No, n (%) 26 (72) 13 (68)  
Anaphylaxis history    0.0753
 Yes, n (%) 4 (11) 6 (32)  
 No, n (%) 28 (78) 13 (68)  
 No history available, n (%) 4 (11) 0 (0)  
Non-asthma atopic disease
 Yes, n (%)
25 (69) 14 (74) 0.6208
 No, n (%) 2 (6) 2 (11)  
 No history available, n (%) 9 (25) 3 (16)  
Food/environmental allergy    0.4649
 Yes, n (%) 21 (58) 11 (58)  
 No, n (%) 5 (14) 5 (26)  
 No history available, n (%) 10 (28) 2 (11)  
Family history of atopic disease    0.2594
 Yes, n (%) 15 (42) 12 (63)  
 No, n (%) 18 (50) 7 (37)  
 No history available, n (%) 3 (8) 0 (0)  
Mean age of asthma onset (range) 36.4 (13–59) 45.8 (13–72) 0.1800
No history available, n (%) 21 (58) 8 (42)  
Mean # of therapies prior to biologic (range) 3.8 (2–8) 3.5 (1–5) 0.6875